Platelet haemostatic function in psychiatric disorders: Effects of antidepressants and antipsychotic drugs

被引:55
作者
Dietrich-Muszalska, Anna [1 ]
Wachowicz, Barbara [2 ]
机构
[1] Med Univ Lodz, Dept Biol Psychiat, Chair Expt & Clin Physiol, Mazowiecka 6-8, PL-92215 Lodz, Poland
[2] Univ Lodz, Dept Gen Biochem, Lodz, Poland
关键词
Platelet activation; psychiatric disorders; platelet haemostatic function; antidepressants; antipsychotics; SEROTONIN REUPTAKE INHIBITORS; GLUTAMATE-RECEPTOR SUPERSENSITIVITY; CORONARY-ARTERY-DISEASE; DENSE GRANULE SECRETION; DEEP VENOUS THROMBOSIS; PLASMINOGEN-ACTIVATOR; MAJOR DEPRESSION; BLOOD-PLATELETS; HEART-DISEASE; RISK FACTOR;
D O I
10.3109/15622975.2016.1155748
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objectives Platelets, the smallest anucleated blood cells, play an essential role in the first step of complex haemostatic process. This review presents the haemostatic function of blood platelets related to their activation in psychiatric disorders (schizophrenia, depression), the role of antipsychotic and antidepressant medication, and introduces the mechanisms by which activated platelets may be involved in the pathophysiology of these disorders. Methods Platelets are interesting and easily accessible blood cells to study biochemical pathways related to schizophrenia and other psychiatric disorders, and their complex activation process might be useful as a diagnostic peripheral marker for studying psychiatric disorders and haemostatic complications. Results The excessive activation of platelets observed in patients with depression and schizophrenia is involved in cardiovascular diseases, stroke and increased risk of thrombotic complications that may be major causes of morbidity and mortality of patients. The use of antidepressants or antipsychotic drugs in depression and schizophrenia treatment is often associated with haematological side effects such as bleeding, venous thromboembolism and impaired platelet function. Conclusions Understanding the role of platelet activation in psychiatric disorders such as schizophrenia or depression and medication may improve therapies in the future.
引用
收藏
页码:564 / 574
页数:11
相关论文
共 123 条
[51]   Association of venous thromboembolism and clozapine [J].
Hägg, S ;
Spigset, O ;
Söderström, TG .
LANCET, 2000, 355 (9210) :1155-1156
[52]  
Hägg S, 2002, CNS DRUGS, V16, P765
[53]  
Hägg S, 2008, DRUG SAFETY, V31, P685
[54]   Risk of venous thromboembolism due to antipsychotic drug therapy [J].
Hagg, Staffan ;
Jonsson, Anna K. ;
Spigset, Olav .
EXPERT OPINION ON DRUG SAFETY, 2009, 8 (05) :537-547
[55]  
Halaris A, 2009, INT ANGIOL, V28, P92
[56]  
Halperin Demian, 2007, Dialogues Clin Neurosci, V9, P47
[57]   Multiple Roles of Tissue Plasminogen Activator in Schizophrenia Pathophysiology [J].
Hoirisch-Clapauch, Silvia ;
Nardi, Antonio E. .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2013, 39 (08) :950-954
[58]   Psychiatric remission with warfarin: Should psychosis be addressed as plasminogen activator imbalance? [J].
Hoirisch-Clapauch, Silvia ;
Nardi, Antonio E. .
MEDICAL HYPOTHESES, 2013, 80 (02) :137-141
[59]   Schizophrenia as a membrane lipid disorder which is expressed throughout the body [J].
Horrobin, DF .
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 1996, 55 (1-2) :3-7
[60]  
Horstman LL, 2010, J NEUROINFLAMM, V3, P7